FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: TempraMed Technologies Ltd. (the "**Issuer**").

Trading Symbol: VIVI

Number of Outstanding Listed Securities: 78,580,705

Date: June 4, 2026

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

   General Overview - The Issuer is focused on the development and marketing of devices that provide temperature protection and "SMART" data collection capability for medications and other substances.

   Its primary operations are all located in Israel while most sales activities are in the USA. Both B2B and direct to consumer.

   To date the issuer has sold more than 125,000 devices worldwide of both VIVI Cap for insulin and GLP-1 and VIVI Epi- for the legacy Mylan EpiPen. Sales of these products continue through B2B and B2C channels while the company works to expand its B2B channels.

   launch "VIVI Cap Smart" and the "Smart Cover" add-on, for the existing installed base of VIVI Cap users was done before year end.

   Additionally, the issuer launched VIVI Med for vials and biologics and a modified VIVI Epi that fits the legacy Mylan EpiPen shape as well as Adrenaclick shape pen.

   The Issuer has opened an additional U.S. manufacturing facility in Florida. The additional site expands the Company's operational capacity and enhances its ability to serve the rapidly growing demand for TempraMed's temperature-stable medication-storage devices across the United States and globally.

   The issuer has entered a strategic media partnership with Dr. Phil's envoy media.

   Listing –

   On October 15, 2025, The Issuer common shares started trading on the CSE under the trading symbol "VIVI".

   During November 2025, The Issuer common shares started trading on the Frankfurt stock exchange under the trading symbol "9DY"

Financing – N/A.

On May 22, 2026, the issuer was Featured on Dr. Phil Show in National US Broadcast Highlighting the Risk of Temperature Exposure for Insulin and Other Medications.

2. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

   N/A.

3. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

   No products or services were discontinued in May 2026.

4. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

   None

5. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

   No expiry or termination of any material contracts or agreements during May 2026.

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

   No acquisitions by the Issuer or dispositions of the Issuer's assets during May 2026.

7. Describe the acquisition of new customers or loss of customers.

   N/A

.

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

On May 14, 2026, the Company’s Indian design application No. 417105-001 for the VIVI Cap Smart™ has been formally granted by the Indian Patent Office.

9. hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

10. Report on any labour disputes and resolutions of those disputes if applicable.

None.

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

13. Provide details of any securities issued and options or warrants granted.

93,750 common shares were issued following the vesting of RSUs and 28,179 common shares were issued following the exercise of stock options.

14. Provide details of any loans to or by Related Persons.

None.

15. Provide details of any changes in directors, officers or committee members.

None.

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

None.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: June 4, 2026.

Gabriel Kabazo
Name of Director or Senior Officer

/S/ "Gabriel Kabazo"
Signature

CFO
Official Capacity

Issuer Details Name of Issuer TempraMed Technologies Ltd.	For Month End May 31, 2026	Date of Report June 4, 2026
Issuer Address 504-9300 Parksville Drive		
City/Province/Postal Code Richmond, B.C. V7E 4W2	Issuer Fax No. N/A	Issuer Telephone No. (604) 833 6820
Contact Name Gabriel Kabazo	Contact Position CFO	Contact Telephone No. (604) 833 6820
Contact Email Address gkabazo@gmail.com	Web Site Address https://tempramed.com/	